Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
apalutamide + leuprolide
- Development stage
- Phase 2
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules, Peptides
- Administration
- Oral, Intramuscular
01
Overview
This combination therapy consists of **apalutamide**, a second-generation androgen receptor antagonist, and **leuprolide**, a gonadotropin-releasing hormone (GnRH) agonist. Apalutamide works by binding directly to the ligand-binding domain of the androgen receptor, inhibiting nuclear translocation and DNA binding, thereby preventing testosterone from promoting prostate cancer cell growth. Leuprolide acts by initially stimulating but subsequently desensitizing GnRH receptors in the pituitary gland, leading to a profound reduction in testicular testosterone production (chemical castration). This specific regimen utilizes an intermittent hormone therapy (IHT) approach, where leuprolide is administered in cycles to allow for testosterone recovery periods, aimed at improving quality of life and delaying the development of castration resistance. The combination is currently being evaluated by The University of Texas Health Science Center at Houston for the treatment of men with biochemically recurrent prostate cancer.
- Other names
- Apalutamide Plus Intermittent Hormone TherapyApalutamide + Leuprolide
02
Targets
AR (Adrenergic receptors)GnRHR (Gonadotropin-releasing hormone receptor)
Beyond the preview
Go deeper on apalutamide + leuprolide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on apalutamide + leuprolide.